Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RPRX
ROYALTY PHARMA PLC
NASDAQ
$63.88
▲ UP 1.22% (0.77)

KEY STATISTICS

Market Cap$28.21 B
52w High$63.94
52w Low$34.08
Dividend Yield1.58%
FrequencyQuarterly
P/E12.17
Volume2.76M
Shares Out.443.27M

COMPANY

LEADERSHIP

Pablo Legorreta
CHIEF EXECUTIVE
Pablo Legorreta

COMPENSATION 2026

Salary$937,500
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$937,500

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 16, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
100

PRICE TARGET

Target High$66.00
Target Low$57.00
Target Median$65.00
Target Consensus$62.67

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$877.37M
NOV
4
WED

PRICE

$63.88 ▲ UP 1.22% (+$0.77)
$62.80$63.20$63.60$64.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM63.88

About Royalty Pharma plc

https://www.royaltypharma.com ↗

Royalty Pharma plc is a U.S.-based company that acquires and manages royalties on biopharmaceutical therapies, collaborating with innovators across academia, biotech, and pharma to support a diverse portfolio of marketed and development-stage ther...

INDUSTRY

Medical - Pharmaceuticals

A SERVICE ROYALTY PHARMA PLC IS KNOWN FOR

Biopharmaceutical Royalty Acquisition and Funding

Royalty Pharma funds biopharmaceutical innovation by acquiring royalty interests in late-stage and commercialized drugs, offering non-dilutive capital to drug developers in exchange for a share of future sales.

COMPETITORS

COMPETITOR
BMY COMPARE
HRMY COMPARE
JAZZ COMPARE
LGND COMPARE
ZTS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Financial Royalty Assets$578.81M $592.43M ▲$594.99M ▲$638.03M ▲
Royalty Income Other$30.48M $29.56M ▼$35.58M ▲$36.11M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
649
LISTED HERE
26
RANKED BY POSITION SIZE
FLCB
0.15% · 5.0M
VXF
0.27% · 4.5M
VFLO
1.59% · 2.9M
IWR
0.19% · 1.7M
CGDG
1.24% · 1.1M
SCHM
0.46% · 1.1M
VETS
1.51% · 662.9K
GSLC
0.24% · 603.1K
JQUA
0.28% · 385.7K
FPX
1.60% · 373.5K
PBE
4.87% · 372.4K
XAMB.DE
0.50% · 367.0K
DBZN.DE
2.81% · 363.0K
INFL
1.26% · 333.2K
NULV
0.76% · 307.7K
OUSM
2.16% · 289.9K
TSME
1.70% · 236.3K
AUSF
1.57% · 231.2K
FUSA.L
0.65% · 224.5K
SM
SMRI
1.89% · 218.2K
JHMM
0.18% · 182.7K
ELCV
3.89% · 170.5K
LGLV
0.83% · 163.9K
XZ
XZME.F
0.09% · 140.2K
SEAC.DE
0.11% · 129.9K
TFGZ
3.14% · 117.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
57.51%
HOLDERS
755
TOP 12 OF 755 · RANKED BY POSITION SIZE
Morgan Stanley
55.3M sh · $2.14B
Capital International Investors
35.3M sh · $1.98B
Fmr LLC
28.0M sh · $987.37M
Blackrock, Inc.
27.8M sh · $1.56B
Blackrock Inc.
23.0M sh · $606.97M
Baillie Gifford & Co
17.4M sh · $612.9M
State Street Corp
12.3M sh · $691.8M
Swedbank Ab
12.2M sh · $430.43M
Adage Capital Partners Gp, L.L.C.
12.0M sh · $422.15M
Price T Rowe Associates Inc /Md/
11.2M sh · $627.63M
Vanguard Group Inc
10.9M sh · $385.84M
Capital World Investors
9.5M sh · $533.64M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity4
Return On Assets4
Debt To Equity1
Price To Earnings2
Price To Book2
Overall Score3

INSIDER TRADES

★
OFFICER: EVP & CHAIRMAN, PARTNERING
Hite Christopher
Sale · 16.8K shares
2026-08-19
★
OFFICER: EVP & CHAIRMAN, PARTNERING
Hite Christopher
Sale · 100.0K shares
2026-08-18
★
OFFICER: EVP & CFO
Coyne Terrance P.
Sale · 9.2K shares
2026-08-13
★
OFFICER: EVP & CFO
Coyne Terrance P.
Sale · 1.8K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
5 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT TD Cowen BUY Citigroup BUY UBS BUY Morgan Stanley OVERWEIGHT

SECTORS PEERS

PEERPRICE
INCY$128.57COMPARE
ROIV$34.20COMPARE
THC$264.06COMPARE
GMAB$34.23COMPARE
UTHR$488.89COMPARE
EXEL$59.40COMPARE
SMMT$16.89COMPARE
FMS$22.45COMPARE